Current reports May 10, 2021
Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information
Content of the report:
Management Board of Celon Pharma S.A. (“Company”) informs that on May 10, 2021 a resolution was adopted concerning the issue of not less than 1 and not more than 15,000,000 D-series common bearer shares, as part of increasing the Company's authorized share capital. At the same time, Company’s Management Board has decided to repeal the resolution concerning the issue of shares, as part of increasing its authorized share capital, adopted on March 5, 2021, as a conditional resolution (The Company informed about the adoption of this resolution in current report no. 14/2021). The Company encloses a copy of the resolution adopted on May 10, 2021.
Company's Management Board advises that the resolution concerning the authorisation of the Management Board to increase the share capital within the authorized capital, together with the possibility for the Management Board to exclude the pre-emptive rights, issued within the authorized capital, in whole or in part, with the consent of the Supervisory Board, was adopted by the Company’s Extraordinary General Meeting on February 16, 2021 (current report No. 9/2021), and the information about registration of the relevant amendments to the Company’s Articles of Association, and the information about the entering of the share capital into the National Court Register was released in current reports No. 20/2021 and 21/2021, on April 12, 2021 and May 6, 2021, respectively.